Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab for cancer cachexia with elevated GDF-15 (PROACC-1)
2023-510446-24-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ponsegromab in cancer anorexia-cachexia syndrome (CACS) (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline body weight at Week 12. Started Mar 2024; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2023-510446-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510446-24-00.